Abstract 377P
Background
Few treatment options are available for patients with metastatic breast cancer (MBC) after standard early lines of chemotherapy. Trifluridine/tipiracil (FTD/TPI, alias TAS-102) has demonstrated survival benefit in heavily pre-treated patients with metastatic colorectal and gastric cancer, refractory to fluoropyrimidines. Advantages of FTD/TPI are oral use, no hand/foot syndrome, lack of cardiotoxicity and no dependency on the DPD enzyme. This phase II study investigated the efficacy of FTD/TPI in patients with ER+, HER2- MBC pre-treated with regular endocrine therapy lines and at least 2 lines of chemotherapy, including a taxane and capecitabine.
Methods
This trial was an open-label, single-arm, multicenter phase II study conducted in ten Dutch hospitals. The primary endpoint was progression-free survival (PFS) rate at 8 weeks. Secondary endpoints included PFS, overall survival (OS), best overall response, safety and quality of life. The primary endpoint was considered met, justifying further research into this treatment regimen, if the lower boundary of the 80% confidence interval (CI) exceeded 30%.
Results
Fifty eligible patients were enrolled, with a median of 3 previous endocrine therapy lines and 2 chemotherapy lines for MBC. The PFS rate at 8 weeks was 64.0% (95% CI: 50.1-75.9%; 80% CI: 55.0-72.1%), thereby meeting the primary endpoint of this study. The median PFS was 5.4 months (95% CI: 2.0-7.2 m), with the duration of previous capecitabine treatment showing no effect on PFS (p = 0.616). The PFS rate at 1-year was 23.7% (95% CI: 12.1-37.4%). One patient had a complete overall response. The median OS was 14.0 months (95% CI: 8.8-17.8 m). The safety profile of FTD/TPI aligned with expected toxicities, including leucopenia, neutropenia, and fatigue. There were no relevant changes in quality of life scores during treatment.
Conclusions
FTD/TPI demonstrated highly promising efficacy in heavily pre-treated patients with MBC, despite prior exposure to a fluoropyrimidine. The advantages of oral administration and the maintenance of quality of life suggest that it holds potential as a viable treatment option. Preparations are underway to initiate a randomized phase III trial.
Clinical trial identification
NCT04489173 (release date: 28-07-2020).
Editorial acknowledgement
Legal entity responsible for the study
Borstkanker Onderzoek Groep Borstkanker Onderzoek Groep Borstkanker Onderzoek Groep (BOOG).
Funding
Servier.
Disclosure
R.H. Mathijssen: Financial Interests, Institutional, Invited Speaker: Bayer, Novartis; Financial Interests, Institutional, Advisory Board: Servier, NaDeNo Nanoscience; Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis, Nordic Pharma; Financial Interests, Institutional, Coordinating PI: Pamgene; Financial Interests, Institutional, Funding: Echo Pharmaceuticals, Deuter Oncology. M. De Boer: Financial Interests, Personal, Other, Member of Data Safety Monitoring Board: Novartis; Financial Interests, Institutional, Invited Speaker: Gilead, Pfizer; Financial Interests, Institutional, Funding, Institutional research grant: Novartis; Financial Interests, Institutional, Research Grant, Institutional research grant: E. Lilly; Financial Interests, Institutional, Research Grant: Pfizer, Roche, AstraZeneca, Daiichi Sankyo, Gilead. M.M. van Rosmalen: Financial Interests, Personal, Writing Engagement, Poster at ONS and article about 'Models of Best Practice - Nurse integration into the BRCA testing pathway': Astrazeneca; Financial Interests, Personal, Other, Creating information material for trastuzumab-deructecan with other nurse practitioners: Astrazeneca. All other authors have declared no conflicts of interest.
Resources from the same session
523P - A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Presenter: Munehiro Wakabayashi
Session: Poster session 15
524P - A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies
Presenter: Ahreum Lim
Session: Poster session 15
525P - Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody
Presenter: Keiji Sugiyama
Session: Poster session 15
526P - Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
Presenter: Maria Elena Elez Fernandez
Session: Poster session 15
527P - Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
Presenter: Josep Tabernero
Session: Poster session 15
529P - Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study
Presenter: Carlo Signorelli
Session: Poster session 15
530P - Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Presenter: Andreas Seeber
Session: Poster session 15
531P - Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database
Presenter: Thierry André
Session: Poster session 15
532P - G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
Presenter: Jean-Baptiste Bachet
Session: Poster session 15